The first annual report of Shanghai Stock Exchange was officially disclosed.
On the 27th, Shanghai Kaikai Industry Company Limited(600272) released its annual report for 2021, which showed that the annual operating revenue was 670 million yuan, a year-on-year decrease of 12.08%; The net profit attributable to the parent company was 21.7172 million yuan, a year-on-year increase of 58.81%; The net profit after deducting non-profit was 4.0343 million yuan, a year-on-year increase of 89.54%; The basic earnings per share was 0.09 yuan, compared with 0.06 yuan in the same period last year.
As of December 31, 2021, Shanghai Kaikai Industry Company Limited(600272) total assets amounted to 1.063 billion yuan, an increase of 19.5022 million yuan or 1.87% over the balance at the end of the previous year; The number of shareholders is 26112.
Source: Shanghai Kaikai Industry Company Limited(600272) Annual Report
Shanghai Kaikai Industry Company Limited(600272) said in the annual report that affected by the market environment, changes in medical reform policies and repeated epidemics, the operating income decreased year by year, affecting the profitability of the company; Most of the annual net profit comes from non operating profits and losses, mainly due to the special subsidy of 10 million yuan for the comprehensive reform project of the clothing sector and 2.9 million yuan for the revitalization of time-honored brands, which is not sustainable.
At the same time, Shanghai Kaikai Industry Company Limited(600272) disclosed the annual profit distribution plan, which plans to distribute profits based on the total share capital registered on the date of equity distribution and equity registration, and distribute cash dividends of RMB 0.27 (including tax) for every 10 shares to all shareholders, with a total dividend of RMB 6.561 million; There is no capital reserve conversion scheme . This plan shall be submitted to the general meeting of shareholders for deliberation and approval before implementation.
According to the annual report, Shanghai Kaikai Industry Company Limited(600272) is mainly engaged in the circulation of traditional Chinese medicine, traditional Chinese medicine service (TCM inquiry service) and clothing wholesale and retail. Among them, the pharmaceutical sector is mainly the wholesale and retail of Chinese and Western patent medicines, as well as the traditional Chinese medicine service with the Chinese time-honored brand “leiyunshang” as the brand and the sales of high-grade tonics of its own brand “shanglei”; The clothing sector is mainly engaged in the wholesale and retail of “Kaikai” brand shirts and sweaters and “Kaikai” brand clothing series.
In terms of remuneration, Shanghai Kaikai Industry Company Limited(600272) chairman Zhuang Qian, aged 48, whose term of office expires on May 28, 2022, did not receive pre tax remuneration from the company and received remuneration from related parties of the company during the reporting period; Zhang Xianghua, vice chairman, is 62 years old. During the reporting period, the total pre tax remuneration received from the company was 880000 yuan.
In fact, Shanghai Kaikai Industry Company Limited(600272) was the first stock to double in the year.
Since the beginning of the year, as of January 17, Shanghai Kaikai Industry Company Limited(600272) has pulled eight trading limits in 10 trading days, and the share price has risen from 9.03 yuan to 17.67 yuan, a record high, with a cumulative increase of more than 100%.
Recent trend of Shanghai Kaikai Industry Company Limited(600272)
During the stock price rise, there were constant rumors about Shanghai Kaikai Industry Company Limited(600272) in the market. It was reported that its subsidiary leiyunshang had a national confidential formula of “Liushen Pill”, and even called Shanghai Kaikai Industry Company Limited(600272) the “king of traditional Chinese medicine”.
In this regard, in the announcement of abnormal fluctuations in stock trading on January 4, Shanghai Kaikai Industry Company Limited(600272) clarified that the company did not have any national confidential pharmaceutical formula, nor did it have the production business of Liushen Pill.
Since then, on January 12, Shanghai Kaikai Industry Company Limited(600272) once again disclosed the stock trading risk warning announcement, saying that the company’s production and operation activities have not changed significantly, and there is no major information that should be disclosed. In recent years, the company’s pharmaceutical circulation business has been under pressure due to the impact of medical reform policies such as volume procurement; At the same time, the healthy transformation of the company needs a long cultivation period, and the investment income is difficult to show in the short term. Please pay attention to the risk of stock investment, beware of the “beating drums and flowers” of hot money in the market, make rational decisions and pay attention to the investment risk.
On January 18, Shanghai Kaikai Industry Company Limited(600272) fell by the limit. Since then, the stock price fluctuated and fell, closing at 9.58 yuan as of January 27.
